Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT107 Dose Escalation in Resistant HCV
NCT01024894Phase 2Unknown
- Sponsor
- Cytheris SA
- Start
- Jan 2009
- Primary completion
- Nov 2012
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant human interleukin-7 in hepatitis C (HCV), sponsored by Cytheris SA. Primary endpoint: Safety of biologically active doses of CYT107 at 12 weeks. Status: unknown.
02
Drugs
recombinant human interleukin-7
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01024894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01024894.